AN2 Therapeutics, Inc.·4

Feb 28, 4:19 PM ET

Prior Stephen David 4

4 · AN2 Therapeutics, Inc. · Filed Feb 28, 2025

Insider Transaction Report

Form 4
Period: 2025-02-26
Prior Stephen David
Chief Strategy Officer
Transactions
  • Award

    Common Stock

    2025-02-26+28,00061,313 total
  • Award

    Stock Option (right to buy)

    2025-02-26+56,00056,000 total
    Exercise: $1.13Exp: 2035-02-25Common Stock (56,000 underlying)
Footnotes (3)
  • [F1]Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
  • [F2]Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
  • [F3]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4